脾切除联合冠腔分流术治疗门静脉高压症的临床疗效

Clinical efficacy of splenectomy combined with coronary-caval shunt in treatment of portal hypertension

  • 摘要: 目的:探讨脾切除联合冠腔分流术治疗门静脉高压症的临床疗效。
    方法:采用回顾性描述性研究方法。收集2001年1月至2015年12月西安交通大学医学院第一附属医院收治的21例门静脉高压症患者的临床资料。患者行脾切除联合冠腔分流术。观察指标:(1)手术情况及手术前、后门静脉系统血流动力学变化:手术时间,术中出血量;门静脉、胃冠状静脉、肠系膜上静脉直径和血流速度。(2)围术期(术前、术后1周、术后1个月)临床指标:①血常规:RBC、WBC、PLT计数;②肝功能:ChildPugh评分、ALT、TBil、Alb、PT延长时间、国际标准化比值。(3)随访情况:术后1、3、5年并发症(上消化道再出血、腹腔积液、肝性脑病、肝衰竭、门静脉和吻合口血栓形成)发生情况。患者出院后定期行门诊或电话随访,术后1年内每3个月随访1次,1年后每6个月随访1次,随访终点事件为患者死亡。随访患者术后并发症(上消化道再出血、腹腔积液、肝性脑病、肝衰竭、门静脉和吻合口血栓形成)发生情况。随访时间截至2016年3月。正态分布的计量资料以±s表示,不同时间点比较采用重复测量方差分析和Student t检验。偏态分布的计量资料以M(范围)表示。
    结果:(1)手术情况及手术前、后门静脉系统血流动力学变化:21例患者均成功完成脾切除联合冠腔分流术,其中19例使用脾静脉搭桥行胃冠状静脉下腔静脉吻合,2例直接行胃冠状静脉下腔静脉吻合。21例患者手术时间为(187±33)min,术中出血量为(233±114)mL。门静脉、胃冠状静脉、肠系膜上静脉直径术前分别为(1.39±0.20)cm、(0.66±0.15)cm、(0.74±0.32)cm,术后分别为(1.36±0.22)cm、(0.42±0.11)cm、(0.81±0.23)cm;血流速度术前分别为(11.2±3.4)cm/s、(6.6±1.3)cm/s、(7.0±2.2)cm/s,术后分别为(10.4±2.5)cm/s、(8.2±2.5)cm/s、(6.9±2.4)cm/s。门静脉、肠系膜上静脉直径手术前、后比较,差异均无统计学意义(t=0.46,-0.81,P>0.05);血流速度手术前、后比较,差异均无统计学意义(t=0.87,0.14,P>0.05)。胃冠状静脉直径、血流速度手术前、后比较,差异均有统计学意义(t=5.91,-2.60,P<0.05)。(2)围术期临床指标变化:①血常规:术前、术后1周、术后1个月血常规RBC计数分别为(2.70±0.50)×1012/L、(3.10±0.60)×1012/L、(3.70±0.20)×1012/L,WBC计数分别为(2.6±2.3)×109、(2.8±2.0)×109、(6.2±1.9)×109,PLT计数分别为(55±28)×109、(248±182)×109、(457±184)×109。术前、术后1周、术后1个月血常规RBC、WBC、PLT计数比较,差异均有统计学意义(F=31.91,11.03,30.74,P<0.05)。其中术后1周血常规RBC、PLT计数与术前比较,差异均有统计学意义(t=-2.35,-4.81,P<0.05);术后1个月血常规RBC、WBC、PLT计数与术后 1周比较,差异均有统计学意义(t=-4.35,-5.65,-3.71,P<0.05)。②肝功能:术前、术后1周、术后 1个月肝功能ChildPugh评分分别为(6.3±1.2)分、(6.2±0.9)分、(6.0±0.6)分,ALT分别为(23± 17)U/L、(44±24)U/L、(36±22)U/L,TBil分别为(28±18)μmol/L、(26±11)μmol/L、(23±8)μmol/L,Alb分别为(31.1±6.8)g/L、(35.0±7.4)g/L、(34.2±2.2)g/L,PT延长时间分别为(4.8±2.1)s、(3.4±2.0)s、(3.7±3.0)s,国际标准化比值分别为1.40±0.20、1.30±0.20、1.50±0.30。术前、术后1周、术后 1个月肝功能ChildPugh评分、TBil、Alb、国际标准化比值比较,差异均无统计学意义(F=1.97,2.60,1.18,1.45,P>0.05);ALT、PT延长时间比较,差异均有统计学意义(F=7.97,4.37,P<0.05)。术后1周ALT、PT延长时间与术前比较,差异均有统计学意义(t=3.23,2.21,P<0.05)。(3)随访情况:21例患者术后均获得随访,随访时间为3~168个月,中位随访时间为37个月。随访期间,3例患者死亡。术后1、3、5年发生上消化道再出血分别为1、1、2例,均予内镜下止血治疗,2例死亡;发生腹腔积液分别为3、2、2例,予对症处理后好转;发生肝性脑病分别为0、0、1例,发生肝衰竭分别为0、0、1例,发生肝性脑病及肝衰竭为同一患者,予保守治疗无效死亡;发生门静脉血栓形成分别为2、2、1例,发生吻合口血栓形成分别为2、1、1例,均予抗凝治疗,其中仅1例发生吻合口血栓形成患者血管再通。
    结论:冠腔分流术属高选择性门腔分流术,区域性降压效果显著,且能保证门静脉入肝血流,术后上消化道再出血、肝性脑病、血栓形成发生率低,是值得推广的治疗门静脉高压症的手术方式。

     

    Abstract: Objective:To investigate the clinical efficacy of splenectomy combined with coronarycaval shunt in treatment of portal hypertension (PHT).
    Methods:The retrospective descriptive study was conducted. The clinical data of 21 patients with PHT who underwent splenectomy combined with coronarycaval shunt at the First Affiliated Hospital of Xi′an Jiaotong University from January 2001 to December 2015 were collected. Observation indicators included (1) operation situations, changes of pre and postoperative portal hemodynamics including operation time and volume of intraoperative blood loss, diameter and blood flow velocity of portal vein (PV), gastric coronary vein and superior mesenteric vein (SMV). (2) Clinical indexes in perioperative period (before operation, at postoperative 1 week and 1 month): ① blood routine test: the counts of red blood cell (RBC), white blood cell (WBC) and platelet (PLT), ② liver function: ChildPugh score, alanine transaminase (ALT), total bilirubin (TBil), albumin (Alb), extended time of prothrombin time (PT) and international normalized ratio (INR). (3) Followup: postoperative 1, 3, 5year complications [upper gastrointestinal rebleeding, peritoneal effusion, hepatic encephalopathy, hepatic failure, portal vein thrombosis (PVT) and anastomotic stoma thrombosis]. The followup using outpatient examination and telephone interview was regularly conducted once every 3 months within postoperative 1 year and once every 6 months after postoperative 1 year up to March 2016 or end of followup (death). Measurement data with normal distribution were presented as ±s. The comparison of different timepoint was analyzed by the repeated measures ANOVA and Student t test. Measurement data with sknewed distribution were presented as M (range).
    Results:(1) Operation situations and changes of pre and postoperative portal hemodynamics: 21 patients underwent successful splenectomy combined with coronarycaval shunt, including 19 receiving splenic vein bypass combined with anastomosis of gastric coronary vein and inferior vena cava and 2 receiving anastomosis of gastric coronary vein and inferior vena cava. Operation time, volume of intraoperative blood loss were (187±33)minutes and (233±114)mL. Diameter and blood flow velocity of PV, gastric coronary vein and SMV were (1.39±0.20)cm, (0.66±0.15)cm, (0.74±0.32)cm, (11.2±3.4)cm/s, (6.6± 1.3)cm/s, (7.0±2.2)cm/s before operation and (1.36±0.22)cm, (0.42±0.11)cm, (0.81±0.23)cm, (10.4±2.5)cm/s, (8.2±2.5)cm/s, (6.9±2.4)cm/s after operation, respectively, showing no statistically significant difference in the diameter and blood flow velocity of PV and SMV before and after operation (t=0.46,-0.81, 0.87, 0.14, P>0.05)and with statistically significant differences in the diameter and blood flow velocity of gastric coronary vein before and after operation (t=5.91,-2.60, P<0.05). (2)Clinical indexes in perioperative period: ① routine blood test: the counts of RBC, WBC and PLT were (2.70±0.50)×1012/L, (2.6±2.3)×109/L, (55±28)×109/L before operation and (3.10±0.60)×1012/L, (2.8±2.0)×109/L, (248±182)×109/L at postoperative 1 week and (3.70±0.20)×1012/L, (6.2±1.9)×109/L, (457±184)×109/L at postoperative 1 month, respectively, with statistically significant differences (F=31.91, 11.03, 30.74, P<0.05). There were statistically significant differences in the counts of RBC and PLT between 1 week postoperatively and before operation (t=-2.35,-4.81, P<0.05) and between 1 month postoperatively and 1 week postoperatively (t=-4.35,-5.65,-3.71, P<0.05). ② Liver function: ChildPugh score, ALT, TBil, Alb, extended time of PT and INR were 6.3±1.2, (23±17)U/L, (28±18)μmol/L, (31.1±6.8)g/L, (4.8±2.1)s, 1.40±0.20 before operation and 6.2±0.9, (44±24)U/L, (26±11)μmol/L, (35.0±7.4)g/L, (3.4±2.0)s, 1.30±0.20 at postoperative 1 week and 6.0±0.6, (36±22)U/L, (23±8)μmol/L, (34.2±2.2)g/L, (3.7±3.0)s, 1.50±0.30 at postoperative 1 month, respectively, showing no statistically significant difference (F=1.97, 2.60, 1.18, 1.45, P>0.05). There were statistically significant differences in the ALT and extended time of PT (F=7.97, 4.37, P<0.05)and in the ALT and extended time of PT between 1 week postoperatively and before operation (t=3.23, 2.21, P<0.05). (3) Followup: 21 patients were followed up for 3-168 months with a median time of 37 months. During followup, 3 patients were dead. One, 1, 2 patients were complicated with upper gastrointestinal rebleeding at postoperative 1, 3, 5 years and received hemostatic therapy under endoscopy, and then 2 were dead. Three, 2 and 2 patients had peritoneal effusion and were improved by symptomatic treatment. One patient had hepatic encephalopathy and hepatic failure at postoperative 5 years and was dead after conservative treatment. PVT and anastomotic stoma thrombosis at postoperative 1, 3, 5 years were detected in 2, 2, 1 and 2, 1, 1 patients, with anticoagulant therapy, and 1 patient received vascular recanalization.
    Conclusion:Coronarycaval shunt is a highly selective portosystemic shunt, it can significantly down regulate the regional pressure while ensure the normal blood flow of liver and decrease the rate of rebleeding, hepatic encephalopathy and thrombosis, meanwhile, it might be a potential therapy in management of PHT.

     

/

返回文章
返回